MARKET

XENE

XENE

Xenon Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.81
-0.13
-1.00%
Closed 16:00 07/02 EDT
OPEN
12.95
PREV CLOSE
12.94
HIGH
13.05
LOW
12.52
VOLUME
58.39K
TURNOVER
--
52 WEEK HIGH
18.45
52 WEEK LOW
7.00
MARKET CAP
448.02M
P/E (TTM)
-9.5769
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average XENE stock price target is 24.00 with a high estimate of 25.00 and a low estimate of 23.00.

EPS

XENE News

More
Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
GuruFocus.com · 06/17 21:04
Hedge Funds Aren’t Done Buying Xenon Pharmaceuticals Inc (XENE)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain
Insider Monkey · 06/08 06:06
Xenon Pharmaceuticals Inc Files For Mixed Shelf Of Up To $250M
Benzinga · 06/03 11:59
Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
BURNABY, British Columbia, June 01, 2020 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone,.
GlobeNewswire · 06/01 20:20
News Flash: Analysts Just Made A Sizeable Upgrade To Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Forecasts
Simply Wall St. · 06/01 16:31
Jefferies Assumes Xenon Pharmaceuticals at Buy, Raises Price Target to $23
Jefferies analyst Andrew Tsai assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and raises Price Target to $23.
Benzinga · 06/01 10:10
71 Biggest Movers From Friday
Gainers Inari Medical, Inc. (NASDAQ: NARI) shares surged 123.7% to close at $42.51 on Friday after pricing its IPO on Friday.
Benzinga · 05/26 08:30
Earnings Beat: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Simply Wall St. · 05/25 13:28

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About XENE

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
More

Webull offers kinds of Xenon Pharmaceuticals Inc stock information, including NASDAQ:XENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XENE stock methods without spending real money on the virtual paper trading platform.